PMGC Holdings notifies availability of NorthStrive Biosciences Phase III AI-driven drug discovery update
PUBT · 07/01 11:36
Share
Listen to the news
- PMGC published a press release on NorthStrive Biosciences’ Phase III AI drug-discovery results with Yuva Biosciences targeting muscle metabolism.
- Four AI-selected small molecules boosted ANT1 expression in primary human skeletal muscle cells; top responses reached 50%.
- Program moves to confirmatory testing in a more mature skeletal muscle model to support further development.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PMGC Holdings Inc. published the original content used to generate this news brief on June 30, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved